"Antisense Therapeutics Limited (“ANP” or “the Company”) is pleased to announce that the US Food and Drug Administration (FDA) has responded affirm atively to the Company’s plan to submit a U.S. Investigational New Drug (IND) application for initiation of longer term Phase IIb human trials of ATL1102 for the treatment of Multiple Sclerosis (MS). Supportive guidance was obtained from the agency’s Pre-IND assessment of the development strategy for ATL1102, including plans for a Phase IIb study in MS patients." -24 OCTOBER 2014
"The Company intends to submit an IND application for a Phase IIb trial in SP-MS patients. The IND application is in preparation and ANP expects to submit the IND with the Food and Drug Administration (FDA) before end 3’Q’2016." -17 JUNE 2016
"ANP to submit a US IND application in early 2017 for Phase
IIb human trial" -4 JAN 2017
How long did you say your oppies had this time Gassy?
Anp Board to bring home the bacon..ROI, page-8
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |